1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed ...
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months). ...
1. Rates of renal insufficiency were highest in patients receiving renal nephrectomy, compared to less invasive treatments. 2. Survival rates ...
1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib ...
1. In a retrospective review of 125 patients with primary renal cell neoplasm that underwent computed tomography (CT), simple renal ...
